Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + icotinib + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy regimen consisting of bevacizumab (a recombinant humanized monoclonal IgG1 antibody that inhibits vascular endothelial growth factor), carboplatin (a platinum-based chemotherapy agent), icotinib (an EGFR tyrosine kinase inhibitor), and pemetrexed (a folate analog that inhibits multiple enzymes in folate metabolism). This combination likely targets multiple cancer pathways simultaneously, including angiogenesis (bevacizumab), DNA synthesis (carboplatin), EGFR signaling (icotinib), and folate metabolism (pemetrexed).
02
Targets
DNADHFR (Dihydrofolate reductase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on bevacizumab + carboplatin + icotinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + icotinib + pemetrexed.